Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.K. sets timetable for containers

This article was originally published in The Tan Sheet

Executive Summary

Firms marketing nonprescription liquid cough and cold drugs in the U.K. must submit to health regulators by Feb. 12, 2010, plans for the child-resistant containers required by September 2010. The Medicines and Healthcare products Regulatory Agency Oct. 27 said it intends to approve changes by the end of March. MHRA imposed the regulation, which covers pharmacy-only and general-sale antihistamines, antitussives, expectorants and decongestants, following a comprehensive efficacy and safety review of children's cough/cold products. MHRA in February 2008 said children under 6 should not use OTC cough/cold products because of efficacy and safety concerns (1"The Tan Sheet" March 9, 2009)

You may also be interested in...

U.K. To Move Kids’ Cough/Cold Drugs BTC, Redraws Age Recommendation

Manufacturers of pediatric cough/cold medicines sold in the U.K. have until March 2010 before the products must be sold behind the pharmacy counter, one of several measures to improve safe use

Akorn Defaults On Loan Agreement After Sale Bid Falls Flat

Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.

Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts